Figure legends.
Figure 1 . Plasmid constructs and design of siRNAs
Schematic representation of the bicistronic expression plasmid coding
genes of firefly luciferase (Luc) and full size RdRp (pRdRp-full) (a)
Nsp1 (pVAX-LP-IRES-LUC) (b), or N (pVAX-N-IRES-LUC) (c) genes of
SARS-CoV-2.
(d) Positions of the siRNA targeting SARS-CoV-2 LP (siLP-1), RdRp
(siR-6-siR-15) and N (siN-2-siN-5) genes. The RT-PCR–amplified region
at the most upstream region of ORF1 (NSP1- leader protein) is marked.
Figure 2. Property of designed siRNA and peptide dendrimer
KK-46
(a-c) Inhibition of gene expression with synthetic siRNA.
Hep-2 cells were transfected with each of the plasmids coding SARS-CoV-2
genes fused with firefly luciferase gene (pRdRp-full) (a),
pVAX-N-IRES-LUC (b) or pVAX-LP-IRES-LUC (c) followed by transfection
with SARS-CoV-2-specific or control siRNA. siLuc and siGFP were used as
positive and negative controls, respectively. LipofectamineTM 3000 was
used as vehicle for both pDNA and siRNA. After 24h cells were harvested
and luciferase activity was determined. Data are expressed as relative
light units (RLU) per 104 cells.
Footnotes: */† or adjusted p value above/below represents the difference
compared to cells transfected with plasmid only/non-specific siGFP,
respectively. *†P<0.05, **††P<0.01,
***P<0.001.
(d) Inhibition of SARS-CoV-2 reproduction with synthetic siRNA.
Vero E6 cells were transfected with siRNA/ LipofectamineTM 3000
complexes. Media with complexes were removed four hours after
transfection and cells were infected with SARS-CoV-2 at MOI 0.0001.
Viral load was determined by qRT-PCR. The results are expressed as viral
RNA copies per mL.
Footnotes: * or p=0.571 represent differences with cells infected with
SARS-CoV-2 and treated with non-specific siLuc. † represent differences
with SARS-CoV-2 only infected
cells.*†P<0.05.
(e) Gene delivery properties of the
peptide dendrimer KK-46
Hep-2 cells were transfected with complexes of pGL3 Luciferase Reporter
Vectors (0.25 μg) and different amounts of peptide dendrimer KK-46
(x-axis) at different ratios 100:1, 50:1, 25:1, 20:1,12.5:1,5:1.
Luciferase activity was evaluated. The pGL3/Lipofectamine 3000 complex
was used as positive controls. Data are expressed as relative light
units (RLU) per 104 cells.
For a-d differences between multiple groups were estimated using a
Kruskal–Wallis test followed by post-hoc testing (if the
Kruskal–Wallis was significant) using un-paired Mann-Whitney U tests.
Bars show medians of five independent experiments+ SDs.
For e differences between multiple groups were analyzed using one-way
analysis of variance (ANOVA) with Tukey’s post hoc test. Bars show
medians of five independent experiments+ SEM. *P<0.05,
**P<0.01.
Figure 3. Modified siRNA have increased resistance to nuclease
degradation. (a) The stability of unmodified siR-7 (circles) and
modified siR-7-EM (squares) in 50% mouse serum are compared over a
period of 264 h at 37°C (N=4). siRNA quantities at various time points
were calculated by dividing the total counts of full-length siRNA by the
input starting material. (b) For this purpose, aliquots of each sample
(10μg siRNA per lane) were analyzed by 1.5% agarose gel
electrophoresis. Differences between multiple groups were analyzed using
repeated measures one-way ANOVA with Dunnetts’s post hoc test. Bars show
medians of four independent experiments+SEM. **** P<0.0001.
Figure 4. Inhibition of SARS-CoV-2 reproduction with unmodified
or LNA-modified siR-7/ peptide dendrimer KK-46 complexes in vitro.
Vero E6 cells were transfected with unmodified siR-7 or LNA-modified
siR-7-EM-peptide dendrimer KK-46 complexes at three concentrations
(x-axes). Media with complexes were removed four hours after
transfection and cells were infected with SARS-CoV-2 at MOI 0.0001.
After 48 hours supernatants and cells were harvested. Viral load was
determined by qRT-PCR in cells lysates (a) and supernatants (b). The
results are expressed as viral RNA copies per mL. Differences between
multiple groups were estimated using a Kruskal–Wallis test followed by
post-hoc testing (if the Kruskal–Wallis was significant) using
un-paired Mann-Whitney U tests. Bars show medians of five independent
experiments + SDs.
Footnotes: # represent differences with cells infected with SARS-CoV-2
and treated with non-specific siLuc.*represent differences with
SARS-CoV-2 only infected cells. *#P<0.05,
**##P<0.01.
Figure 5. Dose-dependent inhibition of SARS-CoV-2 reproduction
with modified siR-7-EM-peptide dendrimer KK-46 complexes in Syrian
hamsters after repeated inhalation exposure.
Syrian hamsters were infected with SARS-CoV-2 with a dose of 105
PFU/animal and treated with three doses of the modified siR-7-EM-peptide
dendrimer KK-46 complexes (35, 98 and 289 μg siR-7-EM/animal, 0.7, 1.96
and 5.6 mg KK-46/kg, respectively). Inhalations with complexes were
repeated daily for six days. Two and six days after infection animals
were sacrificed and determination of viral titer (a) and macroscopic
evaluation plus scoring of histopathology (b) in the lung were
performed. Orally administrated Hydroxychloroquine (within 1 hour after
infection, a dose of 3.8 mg/animal and then daily for 6 days post
infection 1.5 mg/animal) served as control. The results are expressed as
plaque forming units (PFU) per mL (a) or scores (b) obtained for
histological analysis of pathologic alterations in hamsters’ lung. (c)
Dose-response curve of SARS-CoV-2 levels in the lungs at day six after
infection, where the ED50 estimation is ∼ 3.453 mg/kg.
Differences between multiple groups were estimated using a
Kruskal–Wallis test followed by post-hoc testing (if the
Kruskal–Wallis was significant) using un-paired Mann-Whitney U tests.
Bars show medians of one experiment (five animals per group) + SDs. Data
are provided for one experiment representative of two independent
experiments with five hamsters /group.
Footnotes: */† represent differences with hamsters infected with
SARS-CoV-2 and assessed at day two/ six after infection, respectively.
**††P<0.01, *P<0.05.
Figure 6. Effect of
repeated low dose modified siR-7-EM-peptide dendrimer KK-46 complexes in
Syrian hamsters.
Syrian hamsters were infected with SARS-CoV-2 at a dose of 105
PFU/animal and exposed to different doses (0.175, 0.35 and 1.0 mg/kg of
siR-7-EM/KK-46 aerosol) twice a day with two hours interval. Two and six
days after infection animals were sacrificed and viral titers (a) and
macroscopic evaluation and scoring of the histopathology lesions (b) in
the lung were analyzed. Orally administrated Favipiravir (1 hour after
infection, a dose of 1.2 mg/animal was administered twice a day, and
then daily during 6 days after infection 0.4 mg/animal twice a day)
served as positive control. The results are expressed as plaque forming
units (PFU) per mL (a) or scores (b) obtained for histological analysis
of pathologic lung alterations.
Differences between multiple groups were estimated using a
Kruskal–Wallis test followed by post-hoc testing (if the
Kruskal–Wallis was significant) using un-paired Mann-Whitney U tests.
Bars show medians of one experiment (five animals per group) + SDs. Data
are from one experiment representative of two independent experiments
with five hamsters /group are shown.
Footnotes: */† represents difference with hamsters infected with
SARS-CoV-2 and assessed at day two/ six after infection, respectively.
**††P<0.01.